Valted Seq Raises $10.5 Million in Seed Funding Round
GAITHERSBURG, Md.--(BUSINESS WIRE)--Valted Seq, a biotechnology company focused on the genetic elucidation of neurodegenerative disease pathways to accelerate development of new therapeutics and diagnostics, today announced the completion of a seed fundraising round totaling $10.5 million. Dongkoo Bio&Pharma Co. Ltd. led the financing round which also included new investor OV Principal Investments, LLC and several independent investors. Co-Founder D&D Pharmatech was the pre-seed investor at $7 million.
"Today's announcement of our seed funding reflects the interest and excitement of international investors and further validates our compelling technology and vision," said Nina Urban, Valted Seq’s interim CEO. “This financing will accelerate the development of our HiF-Seq platform, generating the largest single-nuclei sequence database for Parkinson’s disease. Interrogating the transcriptomic fingerprints of this highly complex and poorly understood disease will lead to validated drug targets and biomarkers.”
Valted Seq is advancing their proprietary HiF-Seq platform for the collection of single-cell sequencing data from high-quality, clinically characterized post-mortem brain tissues of patients with neurodegenerative diseases such as Parkinson’s and Alzheimer’s. Valted Seq intends to partner with biopharmaceutical companies to broadly leverage the value of the HiF-Seq platform.
The company is also developing minimally invasive assays for:
- Detecting poly (ADP-ribose) (PAR) in cerebral spinal fluid (CSF), serum and serum-derived exosomes for diagnosis of Parkinson’s disease
- Diagnosing Parkinson’s and related α-synucleinopathies through assessment of c-Abl pathway molecules from CSF, serum, or serum-derived exosomes
These proprietary assays are highly specific for their target and have the potential to be used during clinical trials to inform target engagement, patient selection and become companion diagnostic assays.
About Valted Seq
Valted Seq is focused on the discovery of neurodegenerative disease pathways to accelerate development of new therapeutics and diagnostics, including companion diagnostics which play a critical role in enabling advanced therapeutics. Using its HiF-Seq platform, the company has created the world’s largest repository of transcriptomic data from high-quality, clinically characterized brain tissues of patients with neurodegenerative diseases including Alzheimer’s and Parkinson’s. Valted Seq was co-founded in 2019 by Ted Dawson, Valina Dawson and D&D Pharmatech. For more information, please visit www.valtedseq.com.